[go: up one dir, main page]

AR070911A1 - USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA - Google Patents

USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA

Info

Publication number
AR070911A1
AR070911A1 ARP090100937A ARP090100937A AR070911A1 AR 070911 A1 AR070911 A1 AR 070911A1 AR P090100937 A ARP090100937 A AR P090100937A AR P090100937 A ARP090100937 A AR P090100937A AR 070911 A1 AR070911 A1 AR 070911A1
Authority
AR
Argentina
Prior art keywords
pain
par2
antagonist
fracture
inhibitor
Prior art date
Application number
ARP090100937A
Other languages
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR070911A1 publication Critical patent/AR070911A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un antagonista del receptor 2 activado con proteasa (PAR2) para el tratamiento del dolor que incluye el dolor postoperatorio en una incision, el dolor neuropático, el dolor por fractura, el dolor por fractura osteoporotica, el dolor por cáncer de hueso o el dolor articular por gota; el dolor inflamatorio asociado con el síndrome de colon irritable; y la inflamacion relacionada con la artritis reumatoide o la osteoartritis, el antagonista de PAR2 es un anticuerpo anti-PAR2 humano o un fragmento de un anticuerpo que se une al antígeno. Reivindicacion 6: Uso de un antagonista del receptor 2 activado con proteasa (PAR2) segun las reivindicaciones 4 o 5, y uno o varios agentes terapéuticos adicionales seleccionados a partir de otro antagonista de PAR2, un inhibidor de citocina, un fármaco antiepiléptico, un inhibidor de NGF, una colchicina, un fármaco anti-inflamatorio no esteroideo (NSAID), un corticoesteroide y un inhibidor de TNF, en la preparacion de un medicamento para tratar, inhibir o aliviar el dolor asociado con la inflamacion, el dolor postoperatorio en una incision, la neuropatía, la fractura de huesos, la fractura osteoporotica, el cáncer de hueso o la gota.Use of a protease activated receptor 2 (PAR2) antagonist for the treatment of pain that includes postoperative pain in an incision, neuropathic pain, fracture pain, osteoporotic fracture pain, bone cancer pain or joint pain from gout; inflammatory pain associated with irritable bowel syndrome; and inflammation related to rheumatoid arthritis or osteoarthritis, the PAR2 antagonist is a human anti-PAR2 antibody or a fragment of an antibody that binds to the antigen. Claim 6: Use of a protease activated receptor 2 (PAR2) antagonist according to claims 4 or 5, and one or more additional therapeutic agents selected from another PAR2 antagonist, a cytokine inhibitor, an antiepileptic drug, an inhibitor of NGF, a colchicine, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid and a TNF inhibitor, in the preparation of a medication to treat, inhibit or relieve pain associated with inflammation, postoperative pain in an incision , neuropathy, bone fracture, osteoporotic fracture, bone cancer or gout.

ARP090100937A 2008-03-19 2009-03-16 USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA AR070911A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790808P 2008-03-19 2008-03-19
US11915508P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
AR070911A1 true AR070911A1 (en) 2010-05-12

Family

ID=40718925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100937A AR070911A1 (en) 2008-03-19 2009-03-16 USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA

Country Status (6)

Country Link
AR (1) AR070911A1 (en)
CL (1) CL2009000660A1 (en)
PE (1) PE20091693A1 (en)
TW (1) TW201002345A (en)
UY (1) UY31723A (en)
WO (1) WO2009117481A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (en) 2009-09-09 2018-03-08 Regeneron Pharma High affinity human antibodies to human protease-activated receptor-2
US9333152B2 (en) 2011-11-04 2016-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP3049418A1 (en) 2013-09-25 2016-08-03 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
US20190298743A1 (en) * 2016-05-20 2019-10-03 Takeda Pharmaceutical Company Limited Treatment of pain
US20190201454A1 (en) * 2016-06-23 2019-07-04 Mayo Foundation For Medical Education And Research Par2 modulation to alter myelination
CR20190417A (en) 2017-03-16 2019-12-06 Medimmune Ltd Anti-par2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023225A1 (en) * 1995-01-25 1996-08-01 Cor Therapeutics, Inc. Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases

Also Published As

Publication number Publication date
CL2009000660A1 (en) 2010-04-16
PE20091693A1 (en) 2009-11-16
TW201002345A (en) 2010-01-16
WO2009117481A1 (en) 2009-09-24
UY31723A (en) 2009-11-10

Similar Documents

Publication Publication Date Title
AR070911A1 (en) USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA
Yang et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial
Bigoni et al. Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury
Adami et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial
Grossman Lupus arthritis
Ominsky et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
Ong et al. Hyaluronic acid injections in medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty
PE20240913A1 (en) ANTI-IL-2R AGONIST ANTIBODIES AND METHODS OF USE
Watt et al. New drug treatments for osteoarthritis: what is on the horizon?
Chen et al. Arthrofibrosis and large joint scarring
AR081434A1 (en) ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT
CY1118044T1 (en) COMPOSITION PREPARATION WITH COMPETITOR AND CORTICOSTEROIDS
Trueba Davalillo et al. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone
CY1123240T1 (en) ANTI-FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION CONTAINING IT
EA200900709A1 (en) METHODS OF TREATMENT OF CHRONIC INFLAMMATORY DISEASES USING AN ANTAGONIST GM-CSF
Tsai et al. Isorhamnetin ameliorates inflammatory responses and articular cartilage damage in the rats of monosodium iodoacetate-induced osteoarthritis
EA201070725A1 (en) BIS-Pyridylpyridones as antagonists of receptor 1 melaninconcentrating hormone
CL2011002416A1 (en) Use of an anti-il 17a and / or il-17f antibody or antigen-binding fragment thereof that serves in the preparation of a medicament for the treatment of an insulin resistance disorder in a mammal; kit
Kuswanto et al. Repurposing drugs for the treatment of osteoarthritis
CL2015000119A1 (en) The compound (r) -1- (1- (methyl-sulfonyl) -propan-2-yl) -4- (trifluoro-methyl) -1h-indole-5-carbonitrile, androgen receptor modulator; pharmaceutical composition; and its use to treat muscle wasting associated with epoc, with chronic kidney disease, with chronic heart failure, and urinary incontinence, and to accelerate the repair and healing of hip fractures.
King et al. Ketorolac and bone healing: a review of the basic science and clinical literature
y Hernandez et al. Viscosupplementation of the ankle: a prospective study with an average follow-up of 45.5 months
Altman Pharmacological therapies for osteoarthritis of the hand: a review of the evidence
Gossec et al. Do intra-articular therapies work and who will benefit most?
Sewell et al. Emerging injectable therapies for osteoarthritis

Legal Events

Date Code Title Description
FB Suspension of granting procedure